Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

N/A

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(5)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05934630Terminated

Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors

Role: collaborator

NCT04978727Phase 1Active Not Recruiting

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Role: collaborator

NCT04903080Phase 1Active Not Recruiting

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

Role: collaborator

NCT03033992Not ApplicableActive Not Recruiting

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Role: collaborator

NCT03389802Phase 1Active Not Recruiting

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

Role: collaborator

NCT04482933Phase 2Withdrawn

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

Role: collaborator

NCT04201457Phase 1Active Not Recruiting

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Role: collaborator

NCT04295759Phase 1Completed

INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

Role: collaborator

All 8 trials loaded